Justin Kaner, Assistant Director, Hematology and Medical Oncology Fellowship Program at Weill Cornell Medicine Weill Cornell Medicine, shared an article by Jad Othman et al.,on X, commenting:
“Massive NPM1m AML dataset from the Blood Journal out today with some possibly practice changing findings.
1) confirms that post 2nd induction OR 1st consolidation MRD – highly associated with improved OS and lack of benefit of allo sct.
2) the above is true even for FLT3-ITD co mutated pts.
3) confirmation of improved OS with FLAG-Ida-GO -could/should immediately change SOC.
4) Benefit of FLAG-Ida-GO seen in all clinical and genomic subgroups.
5) No prognostic impact of mutations in MDS associated genes.
6) Confirmation, though with caveat of low N, if poor outcomes in pts with adverse CG.
7) worse outcomes with non-ABD NPM1 mutations.
In summary; Massive dataset looking at >1000 NPM1 mutated AML (largest to date) combining RCT data from two large studies between 2009-2020 with likely practice changing findings and important prognostic information regarding the benefit of allo sct in cr1.”
Title: Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Authors: Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Rosemary Gale, Tanya Rapoz-D’Silva, Manohursingh Runglall, Michelle Kleeman, Pawan Dhami, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Brian Huntly, Nigel H Russell and Richard Dillon
Source: Justin Kaner/X
